Clearwater Paper (CLW) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
Achieved $1.6 billion in net sales for 2025, a 12% increase year-over-year, but reported a net loss of $18.6 million.
Completed integration of the Augusta facility and transitioned tissue business, resulting in $52.4 million in cost reductions and SG&A at 6.5% of net sales.
Focused on sustainability, reducing water usage by 7%, achieving BPI compostable certification, and setting a 10% water reduction target by 2030.
Repurchased $17 million in shares, with $79 million remaining in authorization.
Voting matters and shareholder proposals
Election of five directors for one-year terms as part of board declassification.
Ratification of KPMG LLP as independent auditor for 2026.
Advisory vote on executive compensation (say-on-pay).
Approval of amendments to the certificate of incorporation for officer exculpation and to bylaws for a forum selection provision.
Approval of the 2026 Stock Incentive Plan, authorizing 2,000,000 new shares for equity awards.
Board of directors and corporate governance
Board consists of eight members, seven of whom are independent; 57% are diverse by gender or ethnicity.
Board committees (Audit, Compensation, Nominating/Governance) are 100% independent.
Board declassification underway, with annual elections commencing in 2027.
Majority voting standard in uncontested director elections; no poison pill in place.
Stock ownership guidelines require directors to hold stock worth at least five times the annual cash retainer.
Latest events from Clearwater Paper
- Board recommends approval of all director nominees, auditor, compensation, and governance changes.CLW
Proxy filing27 Mar 2026 - Major transformation, cost savings, and ESG progress drive 2026 proxy proposals and governance.CLW
Proxy Filing5 Mar 2026 - Net sales up 12%, Adjusted EBITDA at $107M, but goodwill impairment drove a net loss.CLW
Q4 202518 Feb 2026 - Q2 net sales up 12% but net loss; tissue sale to reduce debt and boost paperboard focus.CLW
Q2 20242 Feb 2026 - Augusta mill acquisition boosts scale and reach as high utilization supports strong margins.CLW
Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - Augusta acquisition and tissue sale drove higher sales, debt reduction, and a paperboard focus.CLW
Q4 202422 Jan 2026 - Q3 sales and volumes rose, but margins fell; $100M buyback and debt reduction followed tissue sale.CLW
Q3 202416 Jan 2026 - Q1 net sales up 46% to $378M, with cost savings and Augusta synergies driving EBITDA growth.CLW
Q1 202523 Dec 2025 - Major strategic shifts, robust governance, and strong ESG focus define this proxy cycle.CLW
Proxy Filing1 Dec 2025